Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Cixutumumab

😃Good
Catalog No. T78279Cas No. 947687-12-9
Alias NSC742460, NSC 742460, LY3012217, LY 3012217, IMC-A12, IMCA12

Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer.

Cixutumumab

Cixutumumab

😃Good
Catalog No. T78279Alias NSC742460, NSC 742460, LY3012217, LY 3012217, IMC-A12, IMCA12Cas No. 947687-12-9
Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$118-In Stock
5 mg$328-In Stock
10 mg$529-In Stock
25 mg$843-In Stock
50 mg$1,130-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.5% (SDS-PAGE); 97.5% (SEC-HPLC)
Contact us for more batch information

Product Introduction

Bioactivity
Description
Cixutumumab (IMC-A12) is a humanized IgG monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It has anticancer activity, inhibits ligand-dependent receptor activation and downstream signaling, and can be used in the study of non-small cell lung and prostate cancer.
In vitro
Cixutumumab showed significant growth inhibition of at least 50% in CHLA-9, TC-71 and Rh41 cell lines after 96 hours of treatment at concentrations ranging from 0.01 to 100 nM. [1]
In vivo
In an in vivo model of the Pediatric Preclinical Testing Program (PPTP), Cixutumumab, given to rats by intraperitoneal injection at a dose of 1 mg twice weekly for six weeks, showed potent antitumor effects and significantly inhibited the progression of solid tumors. [1]
SynonymsNSC742460, NSC 742460, LY3012217, LY 3012217, IMC-A12, IMCA12
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetIGF1-R/IGFR1/CD221
Chemical Properties
Molecular Weight146.32 kDa
Cas No.947687-12-9
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Cixutumumab | purchase Cixutumumab | Cixutumumab cost | order Cixutumumab | Cixutumumab in vivo | Cixutumumab in vitro | Cixutumumab molecular weight